A new Columbia study suggests that malfunctioning endosomes—a central trafficking station inside neurons—are commonly involved in the appearance of Alzheimer’s disease.
Ancient parts of the brain may hold secrets that help explain the drive to eat and how eating may affect brain health. Sabrina Diano, the new Institute of Human Nutrition director, is investigating.
A new study of Alzheimer’s genes suggests the disease in Blacks and whites is largely the same, but genetic changes that increase the risk of developing the disease differ between the two groups.
Months after recovering from a mild case of COVID-19, even healthy young adults are experiencing memory problems, fatigue, mood changes, and other neurological and psychiatric issues.
Patients who experienced delirium were more likely to be cognitively impaired three or more months after the delirium episode, a new study from Columbia researchers has found.
A newly discovered Alzheimer’s gene appears to drive the first appearance of amyloid plaque in the brain and could lead to new therapies that prevent the disease from developing.
Seizures are usually considered a side effect of brain cancer, but a new Columbia University study of mice suggests they may also fuel the further growth of brain tumors.
A new study shows how modifications to the tau protein may influence the different ways it can misfold in the brain, which is closely linked to the type of neurodegenerative disease that develops.
This July, Columbia neurologist Mitch Elkind will become president of the American Heart Association, only the second time a neurologist has led the organization.
Patients taking the recommended diuretic for hypertension experienced more potentially serious side effects than those taking a similar drug, according to a new study from Columbia researchers.
The source of essential tremor—involuntary, rhythmic trembling—has been elusive, but a new study points to abnormal electrical activity in the base of the brain.
Researchers had high hopes for Alzheimer’s drugs that clear amyloid from the brain, but none of the drugs have slowed the disease. Columbia’s Scott Small says he has new reasons to be optimistic.